Bronchogen (Ala-Glu-Asp-Leu): DNA Thermostability and a Sequence Discrepancy

Bronchogen has one published study naming it — a biophysical measurement of its effect on DNA thermostability, which tests the family mechanism at the level of the molecule itself.

· · 2 min read
bronchogen bioregulator khavinson Ala-Glu-Asp-Leu AEDL DNA thermostability respiratory

Key Research Findings

  • Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu (AEDL), C18H30N4O9, 446.46 g/mol, classified as respiratory-associated.
  • Sequence is Ala-Glu-Asp-Leu (AEDL); the only study naming it transposes the middle residues in its title — an error at the source, with no effect on formula or mass.
  • That single study measures the effect on DNA thermostability (PMID 21240358).
  • It is a direct physical test of the family mechanism — peptide interaction with DNA — not a cell or animal study.
  • Nothing in the published record connects the compound to respiratory tissue.
  • No amount is established for any species.

What Bronchogen Is

Bronchogen is a synthetic tetrapeptide, C18H30N4O9, 446.46 g/mol, classified within the bioregulator family as respiratory-associated.

One study names it, and it is an unusually direct one.

Research use only. Supplied for laboratory research. Not for human or veterinary use. No marketing authorisation exists and no therapeutic claim is made.

Sequence: AEDL

The sequence is Ala-Glu-Asp-Leu (AEDL). Worth noting because the title of the single published study naming this compound writes it as Ala-Asp-Glu-Leu, with the middle two residues transposed.

Both orderings contain the same residues, so molecular formula and mass are identical either way — C18H30N4O9, 446.46 g/mol. The ordering is not identical, and AEDL is the correct one. The transposition in that paper title appears to be an error at the source, and is flagged here so that anyone comparing our specification against the citation does not read the difference as a discrepancy in the material.

What the Study Reports

The paper measures the effect of the peptide on DNA thermostability (Monaselidze et al., Bull Exp Biol Med 2011, PMID 21240358).

This matters more than a single citation usually would. The family's proposed mechanism is that short peptides interact directly with DNA. A thermostability measurement is a physical test of exactly that: it asks whether the peptide changes the energy required to denature the double helix. It is not a cell study, not an animal study, and not a respiratory study — it is a measurement of the interaction the whole framework is built on.

Read alongside the chromatin work on Livagen and Prostamax, it forms the small set of papers in this family that test the mechanism rather than assume it.

What Is Not Established

Nothing connects Bronchogen to respiratory tissue in the published record. The bronchial association comes from the family classification scheme. No effect on respiratory epithelium, no safety profile, and no amount for any species has been published.

Structure and Handling

  • Sequence. Ala-Glu-Asp-Leu (AEDL), tetrapeptide.
  • Formula. C18H30N4O9, 446.46 g/mol.
  • Form. Lyophilised powder, ≥98% purity, third-party certificate of analysis per batch.
  • Storage. Sealed vial at −20 °C, protected from light; reconstituted solution at 2–8 °C.
  • Reconstitution. Bacteriostatic water down the vial wall, never onto the powder cake. Do not shake. See the reconstitution calculator.

Chonluten (Thr-Glu-Asp) carries the same respiratory association and has no study naming it. Full family on the bioregulator overview.

Frequently Asked Questions

What is Bronchogen?

Bronchogen is a synthetic tetrapeptide, Ala-Glu-Asp-Leu (AEDL), C18H30N4O9, 446.46 g/mol, classified within the Khavinson bioregulator family as respiratory-associated.

What does the Bronchogen research show?

One study names it: a measurement of its effect on DNA thermostability (PMID 21240358). This is a direct physical test of the family proposed mechanism — whether the peptide changes the energy required to denature the DNA double helix — rather than a cell, animal or respiratory study.

Why does the cited paper write the Bronchogen sequence differently?

The sequence is Ala-Glu-Asp-Leu (AEDL). The title of the only study naming the compound writes Ala-Asp-Glu-Leu, with the middle two residues transposed — an error at the source. Both orderings contain the same residues, so molecular formula and mass are identical (C18H30N4O9, 446.46 g/mol); the ordering is not, and AEDL is correct.

Is the respiratory association supported by research?

No. Nothing in the published record connects Bronchogen to respiratory tissue. The bronchial association comes from the family classification scheme rather than from an experiment.

Is there an established Bronchogen dosage?

No. No controlled human programme exists, so no published figure is available for any species or context.

References

  1. Monaselidze JR, Kiladze MT, Gorgoshidze MZ, Khavinson VKh, Kikalishvili LA, Lomidze EV. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability Bulletin of Experimental Biology and Medicine (2011)
  2. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review Molecules (2021)
Research Use Only: This content is intended for laboratory and scientific research purposes only. It is not intended for human use, medical advice, diagnosis, or treatment. All compounds discussed are for in vitro and preclinical research contexts.

Related Articles

Prostamax (Lys-Glu-Asp-Pro): Chromatin Effects in Human Lymphocytes

Aug 6, 2026 · 2 min

Cardiogen (Ala-Glu-Asp-Arg): Myocardial Tissue Culture and a Sarcoma Model

Aug 6, 2026 · 2 min

Testagen (Lys-Glu-Asp-Gly): Its Only Published Study Is About Metal Corrosion

Aug 6, 2026 · 2 min